A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...
Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...
Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback